Biology
DNA Methylation Patterns in Cancer Epigenetics
Quick fact
In cancer, tumor suppressor genes like p16 and BRCA1 are often silenced by hypermethylation, acting like a 'molecular switch' that turns them off without any mutation.
Why this is interesting
Every cell in your body has the same DNA, yet a liver cell and a neuron look and act completely differently. So how can cancer hijack this system to switch genes on and off at will?
Read the full explanation
Understanding DNA Methylation Patterns in Cancer Epigenetics
Think of DNA as a massive library of instructions, and each cell is a worker that reads only the relevant pages. DNA methylation is like putting sticky notes on the covers of books, telling the worker 'do not read this' or 'read this frequently'. In healthy cells, these sticky notes are carefully placed. In cancer, the sticky notes get misplaced: some genes that should be 'read' (tumor suppressors) get covered with 'do not read' notes (hypermethylation), while some genes that should stay quiet (oncogenes) get 'read this' notes (hypomethylation). This disrupts the cell's normal behavior, pushing it toward uncontrolled growth—cancer. The key point is that the DNA sequence itself doesn't change; only the instruction markers do, which is why this is called 'epigenetic' (meaning 'above genetics').
A deeper explanation
At the molecular level, DNA methylation typically occurs at CpG dinucleotides—cytosines followed by guanines. These CpG sites are clustered in regions called CpG islands, often located in gene promoters. In normal cells, most CpG islands are unmethylated, allowing transcription factors to access and initiate gene expression. In cancer, this balance is lost. Hypermethylation of CpG islands in tumor suppressor gene promoters leads to condensed chromatin and gene silencing, effectively removing brakes on the cell cycle. Simultaneously, global hypomethylation—especially in repetitive sequences and some oncogene promoters—can increase genomic instability and activate growth-promoting genes. These changes are driven by alterations in DNA methyltransferases (DNMTs), the enzymes that add methyl groups, and are maintained as cells divide, making them stable, heritable traits. This dual mechanism is fundamental to cancer initiation and progression. Understanding it has led to the development of epigenetic therapies, such as DNMT inhibitors (e.g., azacitidine) that reverse hypermethylation and reactivate silenced tumor suppressors, and to the use of methylation patterns as diagnostic biomarkers.